LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

Search

Recursion Pharmaceuticals Inc

Suletud

SektorTervishoid

4.84 1.68

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.66

Max

4.9

Põhinäitajad

By Trading Economics

Sissetulek

31M

-172M

Müük

4.4M

19M

Kasumimarginaal

-899.843

Töötajad

800

EBITDA

44M

-148M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+24.74% upside

Turustatistika

By TradingEconomics

Turukapital

-432M

2.1B

Eelmine avamishind

3.16

Eelmine sulgemishind

4.84

Uudiste sentiment

By Acuity

50%

50%

185 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

16. sept 2025, 17:03 UTC

Suurimad hinnamuutused turgudel

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16. sept 2025, 16:49 UTC

Suurimad hinnamuutused turgudel
Omandamised, ülevõtmised, äriostud

GD Culture Shares Drop After Deal for Pallas Capital

16. sept 2025, 16:11 UTC

Suurimad hinnamuutused turgudel

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16. sept 2025, 23:40 UTC

Market Talk

Nikkei May Decline as Yen Strengthens -- Market Talk

16. sept 2025, 23:34 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16. sept 2025, 23:20 UTC

Market Talk

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16. sept 2025, 21:10 UTC

Omandamised, ülevõtmised, äriostud

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16. sept 2025, 20:51 UTC

Market Talk

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16. sept 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

16. sept 2025, 20:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

16. sept 2025, 20:25 UTC

Tulu

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16. sept 2025, 20:24 UTC

Tulu

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16. sept 2025, 19:19 UTC

Market Talk

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16. sept 2025, 18:52 UTC

Market Talk

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16. sept 2025, 18:44 UTC

Market Talk

Global Equities Roundup: Market Talk

16. sept 2025, 18:44 UTC

Market Talk

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16. sept 2025, 18:40 UTC

Omandamised, ülevõtmised, äriostud

Details Emerge on U.S.-China TikTok Deal -- WSJ

16. sept 2025, 18:38 UTC

Market Talk

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16. sept 2025, 18:19 UTC

Market Talk

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16. sept 2025, 18:01 UTC

Market Talk

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16. sept 2025, 17:34 UTC

Market Talk

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16. sept 2025, 16:53 UTC

Tulu

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16. sept 2025, 16:20 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

16. sept 2025, 16:15 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Global Commodities Roundup: Market Talk

16. sept 2025, 16:09 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Global Energy Roundup: Market Talk

16. sept 2025, 16:09 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16. sept 2025, 15:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16. sept 2025, 15:35 UTC

Market Talk

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16. sept 2025, 15:22 UTC

Market Talk

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16. sept 2025, 15:21 UTC

Market Talk

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Recursion Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

24.74% tõus

12 kuu keskmine prognoos

Keskmine 5.95 USD  24.74%

Kõrge 8 USD

Madal 3 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Recursion Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

1

Osta

4

Hoia

0

Müü

Tehniline skoor

By Trading Central

4.15 / 4.75Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

185 / 371 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
help-icon Live chat